In the first semester of 2011, the company reported sales of RON188.46 million and profit of RON7.49 million.
Operating profit in the first six months of 2012 stood at RON4.37 million, while financial profit stood at RON1 million.
Revenue in the first six months grew by 11.1%, from RON191.26 million to RON212.5 million. Expenses increased by 13.5%, from RON182.39 million to RON207.1 million.
Ropharma’s receivables at the end of July were worth RON262.6 million, 5.9% higher on the year. Debts climbed by 17.93% to RON290.68 million.
This year, the company expects sales up 12%, to RON431.5 million (EUR97.1 million) and net profit of RON12.8 million (EUR2.9 million), up 20% on the year.
Mihai Miron indirectly owns 37.65% of Ropharma, through Rimia Investments (20.23%) and ADD Pharmaceuticals (17.72%). USA-registered Arrow Pharmaceuticals controls 31.31% of the company’s stock. Fondul de Pensii Administrat Privat ING, the largest local private pension fund, owns 5.5% of Ropharma.
On August 10 on the Bucharest bourse, Ropharma closed up 0.79% at RON0.635 per share. (EUR1=RON4.5396)